|
|
Previous Article | Table of Contents | Next Article 
Blood, Vol. 91 No. 6 (March 15), 1998:
pp. 1909-1916
The Chemotactic Cytokine Eotaxin Acts as a Granulocyte-Macrophage
Colony-Stimulating Factor During Lung Inflammation
By
Amnon Peled,
Jose Angel Gonzalo,
Clare Lloyd, and
Jose-Carlos Gutierrez-Ramos
From The Center for Blood Research, Inc, and The Department of
Genetics, Harvard Medical School, Boston, MA; and Millennium
Pharmaceuticals, Inc, Cambridge, MA.
 |
ABSTRACT |
During inflammatory processes, inflamed tissues signal the bone
marrow (BM) to produce more mature leukocytes in ways that are not yet
understood. We report here that, during the development of lung
allergic inflammation, the administration of neutralizing antibodies to
the chemotactic cytokine, Eotaxin, prevented the increase in the number
of myeloid progenitors produced in the BM, therefore reducing the
output of mature myeloid cells from BM. Conversely, the in vivo
administration of Eotaxin increased the number of myeloid progenitors
present in the BM. Furthermore, we found that, in vitro, Eotaxin is a
colony-stimulating factor for granulocytes and macrophages. Eotaxin
activity synergized with stem cell factor but not with interleukin-3 or
granulocyte-macrophage colony-stimulating factor and was inhibited by
pertussis toxin. We report also that CCR-3, the receptor for
Eotaxin, was expressed by hematopoietic progenitors (HP). Thus, during
inflammation, Eotaxin acts in a paracrine way to shift the
differentiation of BM HP towards the myeloid lineage.
 |
INTRODUCTION |
DURING INFLAMMATION, the bone marrow (BM)
produces and exports extra mature leukocytes that are required at the
inflammatory site. Cytokines, such as interleukin-5 (IL-5), IL-3, and
granulocyte-macrophage colony-stimulating factor (GM-CSF), produced by
T lymphocytes, were thought to play a critical role in controlling the
differentiation and proliferation of hematopoietic progenitors in the
BM during inflammation.1-5 However, it has been recently
reported that hematopoiesis can take place normally in the complete
absence of signaling events mediated by these cytokines both in steady state and during hematopoietic stress.6 It was therefore
suggested that early phases of hematopoiesis and rapid hematopoietic
responses during inflammation must be dependent on alternative
mechanisms.
It is well documented that, in addition to their function as
chemoattractants, chemokines can also affect the proliferation and/or the differentiation of hemopoietic cells.7,8
Macrophage inflammatory protein-1 (MIP-1 ), a CC chemokine, was
first shown to both inhibit or enhance the proliferation of
hematopoietic progenitors (HP) in response to different
cytokines.9-12 In addition to MIP-1 , transforming growth
factor- (TGF- ) and tumor necrosis factor- (TNF- ) were also
shown to both inhibit or enhance the proliferation of hemopoietic
progenitors in response to other cytokines.13-17
The phenotype of mice deficient for the CXC chemokine, pre-B-cell
growth-stimulating factor (PBSF), further suggested an essential role
for this chemokine in the development of both B-cell lymphopoiesis and
BM myelopoiesis.18-20 The phenotype of IL-8
receptor-deficient mice also suggest a role for IL-8 in controlling the
production of mature hematopoietic cells in the BM.21,22
The fact that chemokines can affect the proliferation and the
differentiation of hematopoietic cells, in addition to their activity
as chemoattractants, prompted us to study their role in controlling the
proliferation and differentiation of HP during inflammation. We focused
our study on Eotaxin, an eosinophil-specific chemoattractant that has
been recently cloned using different rodent models of allergic inflammation.23-26 Using a mouse model of allergic
inflammation, we have previously shown that Eotaxin is upregulated in
the lung within 3 hours of antigen challenge.23,24 We
report here that, during lung allergic inflammation, in addition to its
activity as a chemoattractant, Eotaxin produced at the site of
inflammation can signal to the BM to increase the production and
differentiation of cells from the myeloid lineage.
 |
MATERIALS AND METHODS |
Mice and in vivo procedures.
Eight- to 10-week-old male and female C57BL/6J or Balb/c mice were
purchased from the Jackson Laboratory (Bar Harbor, ME) and kept in the
Center for Blood Research Specific Pathogen Free Mouse Facility.
Pulmonary eosinophilia in response to ovalbumin (OVA; Sigma, St Louis,
MO) was generated in these mice as described.23,24 Briefly,
mice were sensitized with intraperitoneal OVA (0.1 mg/mouse) on day 1 followed by exposure to aerosolized antigen (2% OVA for 5 minutes on
day 8 and 1% OVA for 20 minutes on days 15 through 21) to induce the
response. At different times after allergen challenge, animals were
killed by barbiturate overdose and analyzed. Phosphate-buffered saline
(PBS) was administered (intraperitoneally and aerosolized) to mice as a
negative control. In the blocking experiments, mice were injected with
neutralizing polyclonal antibody against murine Eotaxin (20 µg/mouse,
intravenous)23 30 minutes before OVA administration from
day 15 to day 21 and then analyzed 3 hours after allergen challenge on
the days indicated. OVA-treated control mice were injected with the
same amount of control antibody (Ab; Rabbit Immunoglobulin fraction;
DAKO, Carpenteria, CA) at the same time points indicated
during treatment. No endotoxin contamination was detected in all
reagents used, as assessed by LAL assay (BioWhittaker, Walkersville,
MD). White blood counts and differential counts for
lymphocytes and neutrophils from treated and untreated mice were
performed by Tufts Veterinary Diagnostic Laboratory (Grafton, MA).
GM colony assay.
Murine BM cells were aspirated from the tibia and femurs of BALB/c mice
3 to 4 weeks of age (Charles River Lab, Wilmington, MA),
C57BL/6J mice, or GM-CSF-deficient mice (kindly given by Glenn
Dranoff, Dana Farber Institute, Boston, MA). Erythrocytes were lysed in
ammonium chloride lysis buffer and the cells were washed twice with
PBS. The number of BM cells was counted, and the total number of BM
cells was calculated assuming that the tibia and femurs contain 20% of
the total body BM cells. Lin cells (5 × 103/plate) or BM cells (105/plate) were
cultured in methylcellulose (0.9%) containing Iscove's modified
Dulbecco's medium (IMDM; BioWhittaker) supplemented with 20% fetal
bovine serum (FBS; Intergen, Purchase, NY) and the different growth
factors, and incubated at 37°C in 5% CO2 for 7 days.
Cells were seeded in the concentration of between 10,000 and 5,000 cells/wells (in triplicates). In a different set of
experiments, single cells were seeded (30 cells/96 wells) and 500 wells
were scored. Cells from single colonies in each plate were collected at
day 7 and then washed twice with PBS. The cells were counted
(cells/plate), cytospun, and stained with Giemsa. The number of cells
per colony was calculated by collecting all the cells from a plate and
dividing the number of cells per plate by the number of colonies per
plate.
Cell proliferation assays.
Lin cells were plated into 96-well microtiter plates
at a density of 104 cells/well in IMDM media supplemented
with 10% FBS and 5 × 10 6 mol/L
2- -mercaptoethanol, 1 µCi 3[H] thymidine (Amersham,
Arlington Heights, IL), and the different growth factors.
FDCP-1 and FDCP-MIX cells27,28 were plated into
96-well microtiter plates at a density of 5 × 103
cells/well in IMDM media supplemented with 10% FBS and 5 × 10 6 mol/L 2- -mercaptoethanol, 1 µCi
3[H] thymidine (Amersham), IL-3 (1 ng/mL), and Eotaxin
(10 ng/mL). Cultures were incubated for 24 hours at 37°C in 5%
CO2 and were harvested with a multiple-sample harvester
(Tomtec, Gaithersburg, MD), and their radioactivity was
assessed by a liquid scintillation counter (Betaplate; Wallac, Turku,
Finland). For long-term proliferation, Lin cells or FDCP-1 and FDCP-MIX cells
were seeded in 24-well plates and incubated at 37°C in 5%
CO2 for 1 to 6 days.
Cytokines used in colony and proliferation assays.
Recombinant mouse stem cell factor (rmSCF; Genzyme, Cambridge, MA),
rmIL-3 (Pepro Tech, Rocky Hill, NJ), rmGM-CSF (Immunex, Seattle, WA),
rmMIP-1 (R&D Systems, Minneapolis, MN), and rmEotaxin (lots 095683, I155(D), and I155(M); Pepro Tech) were all used at a concentration of
100 ng/mL. (Eotaxin Lot 105684 had lower activity and was not used
throughout this study.) rmIL-5 was used at 20 ng/mL (R&D), and
rhTGF- (British Bio-technology, Oxon, UK) and rmTNF- (Genentech,
San Francisco, CA) were used at 10 ng/mL and 50 ng/mL, respectively.
Monoclonal antibodies against IL-5 (TRFK-5) were added at a
concentration of 20 µg/mL (kindly provided by P.T. Bozza, Instituto
Oswaldo Cruz-Rio De Janiero, Rio De Janiero, Brazil). Neutralizing
polyclonal antibodies against IL-3 or IL-5 were purchased from R&D
Systems and were used as recommended by the supplier. Pertussis toxin
was purchased from Sigma. The concentration of growth factors used in
this study (as described above) falls within the range of
concentrations used by other investigators in similar studies. Thus,
chemokines such as MIP-1 were generally used at 10 to 1,000 ng/mL,
SCF was at 20 to 200 ng/mL, IL-3 and GM-CSF at 10 to 50 ng/mL, TGF-
at 2 to 20 ng/mL, and TNF- at 10 to 50 ng/mL.11-16,28,29
It should be noticed that the concentrations of IL-3 or GM-CSF used for the studies reported here were higher (100 mg/mL) than the
concentration used by others (10 to 50 mg/mL). Maximal concentrations
of the different growth factors were used throughout this study to get their maximal effect.
Purification of Lin BM cells.
Murine BM cells were aspirated from tibia and femurs of BALB/c mice 3 to 4 weeks of age (Charles River Lab), C57BL/6J mice, or
GM-CSF-deficient mice (kindly given by Glenn Dranoff, Dana Farber
Cancer Institute). Erythrocytes were lysed in ammonium chloride lysis
buffer and the cells were washed twice with PBS. The number of BM cells
was counted, and the total number of BM cells was calculated assuming
that the tibia and femurs contain 20% of the total BM cells. The
Lin cells were selected using previously reported
techniques.29,30 Briefly, 0.5 µg/106 cells of
rat antimouse antibodies specific for RB6-8C5 (GR-1), RA3-6B2 (B220),
MAC-1, Lyt-2 (CD-8), L3T4 (CD-4), and Ter-119 (all purchased from
Pharmingen, San Diego, CA) were added to BM cells and incubated for 20 minutes at 4°C in PBS supplemented with 2% FBS (PBS/FBS). The
cells were washed twice, centrifuged, and resuspended in 3.5 mL PBS/FBS
medium. Sheep antirat IgG immunomagnetic beads (Dynal, Oslo, Norway)
were then added to the cell suspension at a bead to target-cell ratio
of 40:1 and incubated for 20 minutes at 4°C with constant rotation.
The cells were magnetically separated with a particle concentrator
(Dynal) and Lin cells were washed with PBS/FBS and
resuspended in IMDM supplemented with 10% FBS.
Giemsa and immunoflourescence staining for cells collected from GM
colonies and culture plates stimulated with SCF, Eotaxin, and GM-CSF.
To determine the cell type in the GM colonies (or tissue culture
plates), cells taken separately from granulocyte and macrophage type of
colonies were applied to glass slides by cytocentrifugation, air dried
for 10 minutes, and then immersed in Giemsa stain (Sigma), rinsed with
distilled water, air-dried, and mounted. For immunoflourescence staining, cells were stained with fluorescein isothiocyanate
(FITC)/phycoerythrin (PE)-labeled monoclonal antibodies specific for
MAC-1 and GR-1 (PharMingen, San Diego, CA). Briefly, 105
cells were washed with staining buffer (0.1% bovine serum albumin, PBS, 0.02% sodium azide) and incubated with 10 µg/mL (1:50) of purified antimouse CD16/CD32(FcR) (PharMingen) for 20 minutes at
4°C. Cells were then washed with staining buffer and the labeled antibodies were added at a dilution of 1:50 for 20 minutes at 4°C.
The stained cells were washed twice and analyzed by FACSscan flow
cytometer using Cell Quest software (Becton Dickinson, Mountain View,
CA).
 |
RESULTS AND DISCUSSION |
We have recently reported that Eotaxin, an eosinophil-specific
chemoattractant, is highly expressed in the lung during the inflammatory phase of a mouse model of lung allergic
inflammation.23,24 In this model, mice are sensitized with
a single intraperitoneal injection of OVA and then OVA-challenged by
repeated aerosolized exposure at day 8 and daily between days 15 and 21 (Fig 1A). When OVA-treated mice were
analyzed, we found a progressive increase in both the number of
eosinophils infiltrating the lung as well as in the expression of
Eotaxin during the inflammatory phase between days 15 and
21.23,24 Using neutralizing antibodies to Eotaxin, we were
able to partially inhibit (56%) the accumulation of eosinophils in the
lung of OVA-treated mice.23 The assessment of the possible
role that Eotaxin could play on the proliferation and differentiation
of BM hematopoietic progenitors was studied using the same mouse model
of lung inflammation.23,24 We report here that during the
inflammatory phase there was an increase in the number of
granulocyte-macrophage colony-forming units (GM-CFU) in the BM (Fig 1B,
). Interestingly, we also found that during this period there was an
increase in the percentage of neutrophils in the blood from 12% at day
1 of the treatment to 36% by day 21 (Fig 1D). Although transient
elevation of eosinophils in the blood was detected after each OVA
administration, we failed to detect a maintained elevation of
eosinophil numbers in the blood of these OVA-treated mice. We have
previously reported that, during the inflammatory phase of this lung
allergic reaction, there is an eightfold induction of Eotaxin mRNA
levels (relative to 28s rRNA) in the lung as judged by RNAse protection
assay (Gonzalo et al23,24 and data not shown). This
increase in mRNA was paralleled assay by an increase in Eotaxin protein
levels in the serum of OVA treated mice (twofold to fourfold as
estimated by Western blot analysis; data not shown).

View larger version (26K):
[in this window]
[in a new window]
| Fig 1.
During inflammatory processes Eotaxin stimulates the
production of myeloid progenitors in the BM. Mice were sensitized with intraperitoneal OVA on day 0 followed by exposure to aerosolized OVA on
day 8 and on days 15 through 21 (A). In a murine model of lung allergic
inflammation, administration of neutralizing antibodies to Eotaxin
( ) prevented the increase in the number of granulocyte-macrophage
colony-forming units (GM-CFU/BM) in the BM during the inflammatory
phase between days 15 and 21 ( )22 (B). In vivo
administration of Eotaxin increased the number of GM-CFU present in the
BM (C). The increase in the number of blood neutrophils in the blood of
OVA-treated mice is shown in (D). Each point is the mean of three
determinations ± standard deviation (SD). For each panel the
significance of differences between treated and untreated groups of
mice were determined by a standard Student's t-test.
|
|
During this inflammatory phase, Eotaxin expression in the lung
increased23,24 concomitant with an increase in serum
concentration (data not shown). Intravenous administration of
neutralizing antibodies to Eotaxin during the inflammatory phase (day
15 to day 21) totally inhibited the increase in the number of GM-CFU in
the BM (Fig 1B, ). This result suggests a role for Eotaxin in
stimulating the production of myeloid cells in the BM during lung
inflammation. Further analysis of the in vivo effects of Eotaxin was
accomplished by intravenous injection of recombinant Eotaxin into
BALB/c mice. Two days after the administration of Eotaxin, we detected
a significant increase in the number of GM-CFU in the BM (Fig
1C).
The results obtained in vivo indicate that Eotaxin might act as a
proliferation and differentiation factor for hematopoietic cells.
Therefore, we tested the effect of Eotaxin on the proliferation of
Lin hematopoietic progenitors in vitro. Using
thymidine incorporation as a short-term proliferation assay, we found
that Eotaxin could stimulate the short-term proliferation of
Lin cells, as well as SCF, GM-CSF, and IL-3
(Fig 2A1). When Eotaxin was added to cells
stimulated with SCF, it induced an additive proliferative effect (Fig
2A4), but it had no effect on the proliferation of cells stimulated by
GM-CSF or IL-3 (Fig 2A3). As shown previously by others, MIP-1 ,
TGF- , and TNF- by themselves had no proliferative effect on
Lin cells (Fig 2A1). However, as others have
shown,11-16,31,32 when any of these growth factors were
added to cells stimulated by the combination of SCF and IL-3, they
inhibited their proliferation (Fig 2A2). Our results suggest that
Eotaxin acts on the same Lin target cells stimulated
by GM-CSF and IL-3 but not on those stimulated by SCF. Alternatively,
Eotaxin may use the signal transduction pathways used by IL-3 and
GM-CSF but not that used by SCF. Experiments to address these two
possibilities are currently underway.

View larger version (24K):
[in this window]
[in a new window]
| Fig 2.
Eotaxin induced the proliferation and differentiation of
Lin hematopoietic progenitors into granulocytes and
macrophages. Thymidine incorporation (see the Materials and Methods;
measured in counts per minute per well) induced by Eotaxin (A1),
Eotaxin plus SCF and IL-3 (A2), Eotaxin plus IL-3 or GM-CSF (A3), and Eotaxin plus SCF (A4) is shown in (A). Proliferation of
Lin cells (5 × 103) stimulated with SCF,
Eotaxin, or the combination of the two is shown in (B). The expression
of the granulocyte and macrophage cell surface differentiation markers
GR-1 and MAC-1 is shown in (C). Granulocytes that were double-stained
for GR-1 and MAC-1 are marked by an arrow. The percentage of cells
either not expressing MAC-1 and GR-1 or expressing MAC-1 or MAC-1 and
GR-1 is shown at day 4 (C). Three different experiments were performed;
the results shown are of one representative experiment. Each point is
the mean of three to six determinations ± SD.
|
|
We further analyzed the long-term effect(s) of Eotaxin on the
proliferation and differentiation of BM HP by growing the cells in the
presence of Eotaxin. Eotaxin induced the proliferation of
Lin hematopoietic progenitors for up to 4 days (Fig
2B). This proliferative response was coupled with terminal
differentiation of the Lin cells into macrophages
that express the differentiation cell surface marker MAC-1 (34%) and
granulocytes that express the differentiation cell surface markers
MAC-1 and GR-1 (Fig 2C, 32%, arrow). In contrast, most of the cells
proliferating in response to SCF, used as a control, maintained their
blast morphology and did not express either MAC-1 or GR-1 (Fig 2B, 2C,
79%). In agreement with the short-term proliferation assay (Fig 2A),
addition of Eotaxin to cells stimulated with SCF induced an additive
effect on the expansion and differentiation of the MAC-1+
(25%) and MAC-1+/GR-1+ (12%) hematopoietic
cells that were found in the cultures after 4 to 6 days (Fig 2C,
arrow). We therefore concluded that Eotaxin by itself could induce
short-term proliferation and terminal differentiation of hematopoietic
progenitors into macrophages and granulocytes.
Eotaxin was also tested for its ability to stimulate the formation of
GM colonies in methylcellulose. We found that Eotaxin acts as a GM-CSF
for Lin cells in the range of 10 to 100 ng/mL
(Fig 3A). Eotaxin has been shown to induce
chemotaxis of eosinophils in vitro at the same concentration
range.26 In the absence of exogenous growth factors, few,
if any (0 to 2 colonies/500 cells) colonies were observed (Fig 3A). To
rule out an indirect colony-stimulating effect by Eotaxin through the
activation of more mature cells, we performed dilution experiments. We
found a direct correlation between the number of seeded cells and the
number of colonies counted (Fig 3A1). In multiple experiments, we
seeded as few as 100 cells per plate and this resulted in the
generation of 2 to 3 colonies per well (at this concentration of cells,
in the absence of exogenous growth factors, no colonies were detected;
not shown). When we seeded 500 cells per well, we obtained
approximately 20 (18 ± 2, n = 96) colonies per well in
the presence of Eotaxin and 0 to 2 colonies in the absence of exogenous
growth factors. These results suggest that Eotaxin acts directly on the
progenitor cells. However, these results cannot exclude the possibility
that Eotaxin induced secretion of an autocrine growth factor. Eotaxin
stimulated the formation of both macrophages and neutrophil type of
colonies (Fig 3A2). No differences were found in the colony-stimulating activity of Eotaxin when Lin cells purified from Balb/C and C57BL/6J mice were used (data not shown). Eotaxin stimulated the same number of
colonies as GM-CSF, but the Eotaxin-induced colonies were smaller and
the number of cells per colony was between twofold and fivefold lower
(Eotaxin/GM-CSF, ~500 to 1,000/~2,000 to 3,000 cells per colony,
Fig 3B). In control colony assays, both IL-5 and SCF stimulated few
colonies with a low number of cells per colony (Fig 3B). However, when
SCF or IL-5 were added with Eotaxin, only SCF had an additive effect on
the number of GM colonies stimulated by Eotaxin (Fig 3B). The effect of
SCF on the number of cells per colony induced by Eotaxin was
synergistic (Fig 3B and C). In agreement with the short-term
proliferation assay, Eotaxin did not significantly modify the number of
colonies or the number of cells per colony induced by GM-CSF or IL-3
(Fig 3B, data not shown).

View larger version (36K):
[in this window]
[in a new window]
| Fig 3.
Eotaxin is a GM-CSF for Lin hematopoietic
progenitors and can synergize with SCF to stimulate the production of
granulocytes and macrophages. The concentration-dependent
colony-stimulating activity of Eotaxin is shown in (A). The ability of
Eotaxin (100 ng/mL) to stimulate colony formation in Lin
cells seeded in the concentration of 1 to 5,000 cells/plate is shown in
(A1; see the Materials and Methods). Macrophages (M) and
granulocyte-neutrophils (N) types of colonies stimulated by Eotaxin are
shown in (A2). The colony-stimulating activities of Eotaxin, IL-3,
MIP-1 , GM-CSF, SCF, and IL-5 and their combinations are shown ( ).
The number of cells per plate collected from the GM-CFU assay (see the
Materials and Methods) is shown ( ). (C) The pictures of colonies
stimulated by either SCF, Eotaxin, or both were taken at an original
magnification of ×200. Five different experiments were performed. The
results shown are of one representative experiment. Each point is the
mean of three determinations ± SD.
|
|
To rule out possible autocrine GM-CSF secretion by cells stimulated by
Eotaxin, Lin progenitors purified from the BM of
GM-CSF-deficient mice were studied. We found no difference in the GM
colony-stimulating activity of Eotaxin on both Lin
progenitors purified from wild-type or GM-CSF-deficient mice (Fig 4A, ). We also did not find any
difference in the GM colony-stimulating activity of Eotaxin when
neutralizing antibodies to IL-3 or IL-5 were used in these assays (Fig
4A). We therefore concluded that neither IL-3, nor IL-5, nor GM-CSF are
involved in the colony-stimulating activity of Eotaxin. However, this
does not exclude the possibility that other growth factors are involved
in this proliferative response. In addition, the colony-stimulating
activity of Eotaxin was inhibited by (1) treating the protein with
either 1 mmol/L dithiothreitol (DTT) or acetonitrile, (2) boiling, or
(3) neutralizing antibodies to Eotaxin (Fig 4A).

View larger version (28K):
[in this window]
[in a new window]
| Fig 4.
Eotaxin induced the differentiation and proliferation of
hematopoietic progenitors into metamyelocytes and macrophages in a
GM-CSF-independent pathway. (A) Eotaxin was either treated with 1:100
polyclonal antibodies to Eotaxin or 50 µg/mL neutralizing polyclonal
antibodies to IL-3 or to IL-5. As a control, antibodies against Eotaxin
were also mixed with GM-CSF. The treated and untreated Eotaxin and
GM-CSF were then used to perform a GM-CFU assay using Lin cells that were purified from BM of wild-type (WT)
BALB/c mice ( ). Eotaxin was used to stimulate GM colony formation
using Lin cells that were purified from BM of
GM-CSF-deficient mice (KO)3 or wild-type (WT) BALB/c mice
( ). The activity of Eotaxin was inactivated by treatment with 1 mmol/L DTT, acetonitrile (ACN), and boiling for 5 minutes (B). The
results shown in (A) are the mean of three individual experiments ± SD.
|
|
Pertussis toxin blocks cell activation induced by
Gi-protein-coupled receptors. Pretreatment of eosinophils with
pertussis toxin completely inhibited the Eotaxin-induced
responses.33 We therefore tested the effect of
Pertussis toxin on the colony-stimulating activity of Eotaxin.
In the concentration of 100 ng/mL Pertussis toxin inhibited the
number of colonies stimulated by Eotaxin by 40% ± 1.1%
(Fig 5A) and the number of cells produced
in these colonies by 75% ± 8.3% (Fig 5B). As expected, we found
that Lin cells expressed the Eotaxin receptor, CCR-3
(Rothenberg et al,34 Ponath et al,35 Daugherty
et al,36 and data not shown).

View larger version (22K):
[in this window]
[in a new window]
| Fig 5.
Pertussis toxin inhibits the colony-stimulating
activity of Eotaxin. (A) Pertussis toxin in the range of 1 to
100 ng/mL blocked the colony-stimulating activity of Eotaxin (100 ng/mL). The number of cells per plate collected from the GM-CFU assay
is shown in (B). Three different experiments were performed. The
results shown are of one representative experiment. Each point is the
mean of three determinations ± SD.
|
|
We then searched for a mouse myeloid cell line that could respond by
proliferation to Eotaxin. We found that the IL-3-dependent FDCP-1
myeloid cells but not IL-3-dependent FDCP-mix myeloid cells responded
to Eotaxin by proliferation (Fig 6A and B).
SDF-1, MIP-1 , and MCP-1 could not support the proliferation of
FDCP-1 cells. Eotaxin induced a dose-dependent proliferation response
in these cells in concentrations greater than 3 ng/mL (Fig 6C).
Partially purified heparin-bound Eotaxin produced in p3x63 myeloma
cells24 was also able to stimulate the proliferation of
FDCP-1 cells (data not shown). As shown for MIP-1 ,17 the
relatively high doses of Eotaxin needed for the stimulation of HP
proliferation could be the result of an inbalance between the monomeric
form of Eotaxin and its polymerized form.

View larger version (21K):
[in this window]
[in a new window]
| Fig 6.
Eotaxin induces the proliferation of FDCP-1 but not
FDCP-MIX IL-3-dependent myeloid cell lines. FDCP-1 (A) or FDCP-MIX
cells (B) (5,000 cells/well) were seeded in 96-well plates and
supplemented with the different growth factors. Thymidine incorporation
was measured after 24 hours as counts per minute (CPM)/well. FDCP-1 (5 × 103) cells were seeded in 24-well plates and stimulated
with different concentrations of Eotaxin. Cells were collected and
counted after 6 days (C). Five different experiments were performed.
The results shown are of one representative experiment. Each point is
the mean of three determinations ± SD.
|
|
In this study, we have compared the effects of the novel chemokine
Eotaxin along with MIP-1 , TGF- , or TNF- on the proliferation and differentiation of Lin cells. Our results
indicate that Eotaxin by itself or in combination with SCF can
stimulate the proliferation and differentiation of HP cells.
Furthermore, we found that this stimulatory effect was dependent on the
network of cytokines used by these cells. In fact, MIP-1 has been
shown to reversibly inhibit the proliferation of murine day-12
colony-forming units-spleen (CFU-S). MIP-1 was also
shown to enhance IL-3- and GM-CSF-induced colony formation of
Lin progenitors, but had no effect on G-CSF- and
CSF-1-induced colony formation. However, the inhibitory effects of
MIP-1 could only be detected when a combination of two or more
cytokines were used. In human cells, MIP-1 inhibits the
proliferation of CFU-granulocytes, erythrocytes, macrophages,
megakryocytes, burst-forming unit-erythroids, and CFU-GM, whereas more
mature CFU-erythrocytes, CFU-granulocytes, and CFU-GM
progenitors are stimulated.9-12 15,31,32 Although less effective than TGF- and TNF- , in our experiments, MIP-1 also partially blocked the proliferative effect induced by SCF
and IL-3 (Fig 2A). TGF- was shown to inhibit the action of SCF,
IL-3, and CSF-1 on mouse hematopoietic progenitors. It was also shown
to inhibit primitive HP cells, whereas more mature cells were not
affected. However, TGF- was also shown to enhance the growth of BM
progenitors in response to GM-CSF.15,16,28 TNF- was
shown to inhibit the proliferation of primitive Lin
and Lin SCA-1+ cells. It was also shown
to inhibit the proliferation of HP cells induced to proliferate by SCF.
The stimulatory effects of TNF- were shown to be indirect and were
the result of increased production of IL-3 and GM-CSF.13-15
TNF- , TGF- , and MIP-1 were shown by us to inhibit the
proliferation of Lin cells in response to SCF and
IL-3. By themselves, none of these stem cell inhibitors could induce
proliferation of Lin cells (Fig 2A1). SCF was shown
to induce the proliferation of primitive HP cells. In vivo, this
stimulation was coupled with increased myeloid
differentiation.28,29
During inflammation, signals produced at the site of injury enhance the
production and migration of mature leukocytes from the BM. It has been
believed that IL-3/GM-CSF/IL-5 produced by T cells play a major role in
the expansion of hematopoietic cells in an emergencies. However, it was
recently shown that the entire function of the IL-3/GM-CSF/IL-5 is
dispensable for hematopoiesis in an emergencies as well as in a steady
state.6 These investigators suggest the existence of an
alternative mechanism to produce blood cells in both situations. Our
results indicate that chemokines might be involved in such an
alternative mechanism.
We have shown in this study that the chemotactic cytokine Eotaxin can
act both in vivo and in vitro as a growth and differentiation factor
for myeloid hematopoietic progenitors. Our results suggest that Eotaxin
produced at inflammatory sites can stimulate the differentiation and
proliferation of myeloid progenitors in the BM, thereby contributing to
the generation of mature leukocytes needed to perform the inflammatory
reaction.
 |
FOOTNOTES |
Submitted January 29, 1997;
accepted October 30, 1997.
Supported by National Institutes of Health Grants No. HL 148675-02, CiCyT PB93-0317, HL94-10-B, and HL36028 and by the Aplastic Anemia
Foundation of America grants. J.-C.G.-R. is the Amy C. Potter Fellow.
A.P. is a recipient of the Dorot Fellowship of the Israeli Academy of
Science and Harvard Medical School. J.A.G. is a recipient of the
postdoctoral Fellowship from the Spanish Ministry of Science.
Address reprint requests to J.-C. Gutierrez-Ramos, PhD,
Millennium Pharmaceuticals, Inc, 640 Memorial Dr, Cambridge, MA
02139-4815.
The publication costs of this article were defrayed in part by page
charge payment. This article must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. section
1734 solely to indicate this fact.
 |
ACKNOWLEDGMENT |
The authors are indebted to Barrett Rollins and Frank Lee for critical
reading of this manuscript. We thank G.-Q. Jia and M. Bozza for their important suggestions and continuous support of this
project and C. Martinez-Alonso and J.P. Albar for the neutralizing polyclonal antibodies against murine Eotaxin. The authors
thank Marci Melzer for her editorial assistance.
 |
REFERENCES |
1.
Kopf M,
Brombacher F,
Hodgkin PD,
Ramsay AJ,
Milbourne EA,
Dai WJ,
Ovington KS,
Behm CA,
Köhler G,
Young IG,
Matthaei KI:
IL-5-deficient mice have a developmental defect in CD5+ B-1 cells and lack eosinophilia but have normal antibody and cytotoxic T cell responses.
Immunity
4:15,
1996[Medline]
[Order article via Infotrieve]
2.
Till S,
Li B,
Durham S,
Humbert M,
Assoufi B,
Huston D,
Dickason R,
Jeannin P,
Kay AB,
Corrigan C:
Secretion of the eosinophil-active cytokines interleukin-5, granulocyte/macrophage colony-stimulating factor and interleukin-3 by bronchoalveolar lavage CD4+ and CD8+ T cell lines in atopics asthmatics, and atopic and non-atopic controls.
Eur J Immunol
25:2727,
1995[Medline]
[Order article via Infotrieve]
3.
Dranoff G,
Crawford AD,
Sadelain M,
Ream B,
Rashid A,
Bronson RT,
Dickersin GR,
Bachurski CJ,
Mark EL,
Whitsett JA,
Mulligan RC:
Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis.
Science
264:713,
1994[Abstract/Free Full Text]
4. Xing Z, Braciak T, Ohkawara Y, Sallenave J, Foley R, Sime J,
Jordana M, Graham F, Gauldie J: Gene transfer for cytokine functional
studies in the lung: The multifunctional role of GM-CSF in pulmonary
inflammation. J Leukoc Biol 59:481, 199
5.
Warren D,
Moore M:
Synergism among interleukin 1, interleukin 3, and interleukin 5 in the production of eosinophils from primitive hematopoietic stem cells.
J Immunol
140:94,
1988[Abstract]
6.
Nishinakamura R,
Miyajima A,
Mee P,
Tybulewicz V,
Murry R:
Hematopoiesis in mice lacking the entire granulocyte-macrophage colony-stimulating factor/interleukin-3/interleukin-5 functions.
Blood
88:2458,
1996[Abstract/Free Full Text]
7.
Schall TJ,
Bacon KB:
Chemokines, leukocyte trafficking, and inflammation.
Curr Opin Immunol
6:865,
1994[Medline]
[Order article via Infotrieve]
8.
Kita H,
Gleich GJ:
Chemokines active on eosinophils: Potential roles in allergic inflammation.
J Exp Med
183:2421,
1996[Free Full Text]
9.
Cook DN,
Beck MA,
Coffman TM,
Kirby SL,
Sheridan JF,
Pragnell IB,
Smithies O:
Requirement of MIP-1 for an inflammatory response to viral infection.
Science
269:1583,
1995[Abstract/Free Full Text]
10.
Graham GJ,
Wright EG,
Hewick R,
Wolpe SD,
Wilkie NM,
Donaldson D,
Lorimore S,
Pragnell IB:
Identification and characterization of an inhibitor of haemopoietic stem cell proliferation.
Nature
344:442,
1990[Medline]
[Order article via Infotrieve]
11.
Broxmeyer HE:
Myelopoietic enhancing effects of murine macrophage inflammatory proteins 1 and 2 on colony formation in vitro by murine and human bone marrow granulocyte/macrophage progenitor cells.
J Exp Med
170:1583,
1989[Abstract/Free Full Text]
12.
Verfaillie CM,
Catanzarro PM,
Wen-na L:
Macrophage inflammatory protein 1 , interleukin 3 and diffusible marrow stromal factors maintain human hematopoietic stem cells for at least eight weeks in vitro.
J Exp Med
179:643,
1994[Abstract/Free Full Text]
13.
Jacobsen FW,
Dubois CM,
Rusten LS,
Veiby OP,
Jacobsen SEW:
Inhibition of stem cell factor-induced proliferation of primitive murine heamatopoietic progenitor cells Signaled through the 75-kilodalton tumor necrosis factor receptor.
J Immunol
154:3732,
1995[Abstract]
14.
Jacobsen SE,
Ruscetti FW,
Dubois CM,
Keller JR:
Tumor necrosis factor alpha directly and indirectly regulates hematopoietic progenitor cell proliferation: Role of colony-stimulating factor receptor modulation.
J Exp Med
175:1759,
1992[Abstract/Free Full Text]
15.
Bonnet D,
Lemoine FM,
Najman A,
Guigon M:
Comparison of the inhibitory effect of AcSDKP, TNF- , TGF- , and MIP-1 on marrow-purified CD34+ progenitors.
Exp Hematol
23:551,
1995[Medline]
[Order article via Infotrieve]
16.
Keller JR,
Jacobsen SE,
Dubois CM,
Hestdal K,
Ruscetti FW:
Transforming growth factor-beta: A bidirectional regulator of hematopoietic cell growth.
Int J Cell Cloning
10:2,
1992[Abstract]
17.
Cooper S,
Mantel C,
Broxmeyer HE:
Myelosuppressive effects in vivo with very low dosages of monomeric recombinant murine macrophage inflammatory protein-1 .
Exp Hematol
22:186,
1995
18.
Tashiro K,
Tada H,
Heiker R,
Shirozu M,
Nakano T,
Honjo T:
Signal sequence trap: A cloning strategy for secreted proteins and type I membrane proteins.
Science
261:600,
1993[Abstract/Free Full Text]
19.
Nagasawa T,
Kikutani H,
Kishimoto T:
Molecular cloning and structure of a pre-B-cell growth-stimulating factor.
Proc Natl Acad Sci USA
91:2305,
1994[Abstract/Free Full Text]
20.
Nagasawa T,
Hirota S,
Tachibana K,
Takakura N,
Nishikawa S,
Kitamura Y,
Yoshida N,
Kikutani H,
Kishimoto T:
Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1.
Nature
382:635,
1996[Medline]
[Order article via Infotrieve]
21.
Cacalano G,
Lee J,
Kikly K,
Ryan AM,
Pitts-Meek S,
Hultgren B,
Wood WI,
Moore MW:
Neutrophil and B cell expansion in mice that lack the murine IL-8 receptor homolog.
Science
265:682,
1994[Abstract/Free Full Text]
22.
Shuster DE,
Kehrli ME Jr,
Ackermann MR:
Neutrophilia in mice that lack the murine IL-8 receptor homolog.
Science
269:1590,
1995[Free Full Text]
23.
Gonzalo JA,
Lloyd CL,
Kremer L,
Finger E,
Martinez-Alonso C,
Siegelman MH,
Cybulski M,
Gutierrez-Ramos JC:
Eosinophil recruitment to the lung in a murine model of allergic inflammation: The role of T cells, chemokines and endothelial adhesion receptors.
J Clin Invest
98:1,
1996[Medline]
[Order article via Infotrieve]
24.
Gonzalo JA,
Jia G-Q,
Aguirre V,
Friend D,
Coyle AJ,
Jenkins NA,
Lin GS,
Katz H,
Litchman A,
Copeland N,
Kopf M,
Gutierrez-Ramos JC:
Mouse eotaxin expression parallels eosinophil accumulation during lung allergic inflammation but it is not restricted to a Th2-type response.
Immunity
4:1,
1996[Medline]
[Order article via Infotrieve]
25.
Rothenberg ME,
Luster AD,
Lilly CM,
Drazen JM,
Leder P:
Constitutive and allergen-induced expression of Eotaxin mRNA in the guinea pig lung.
J Exp Med
181:1211,
1995[Abstract/Free Full Text]
26.
Rothenberg ME,
Luster AD,
Leder P:
Murine Eotaxin: An eosinophil chemoattractant inducible in endothelial cells and in interleukin 4-induced tumor suppression.
Proc Natl Acad Sci USA
92:8960,
1995[Abstract/Free Full Text]
27.
Spooncer E,
Heyworth CM,
Dunn A,
Dexter TM:
Self renewal and differentiation of IL-3-dependent multipotential stem cells are modulated by stromal cells and serum factors.
Differentiation
31:111,
1986[Medline]
[Order article via Infotrieve]
28.
Dubois CM,
Ruscetti FW,
Stankova J,
Keller JR:
Transforming growth factor- regulates c-kit message stability and cell-surface protein expression in hematopoietic progenitors.
Blood
83:3138,
1994[Abstract/Free Full Text]
29.
Brandt J,
Briddell RA,
Srour EF,
Leemhuis TB,
Hoffman R:
Role of c-kit ligand in the expansion of human hematopoietic progenitor cells.
Blood
79:634,
1992[Abstract/Free Full Text]
30.
Spangrude GJ,
Heimfeld S,
Weissman IL:
Purification and characterization of mouse hematopoetic stem cells.
Science
241:58,
1988[Abstract/Free Full Text]
31.
Keller JR,
Bartelmez SH,
Sitnicka E,
Ruscetti FW,
Ortiz M,
Gooya JM,
Jacobsen SEW:
Distinct and overlapping direct effects of macrophage inflammatory protein-1 and transforming growth factor on hematopoietic progenitor/stem cell growth.
Blood
84:2175,
1994[Abstract/Free Full Text]
32.
Mayani H,
Little M,
Dragowska W,
Thornbury G,
Lansdrop P:
Differential effects of the hematopoietic inhibitors MIP-1 , TGF- , and TNF- on cytokine-induced proliferation of subpopulation of CD34+ cells purified from cord blood and fetal liver.
Exp Hematol
23:422,
1995[Medline]
[Order article via Infotrieve]
33.
Tenscher K,
Metxner B,
Schopf E,
Norgauer J,
Czech W:
Recombinant human Eotaxin induces oxygen radical production, Ca2+-mobilization, actin reorganization, and CD11b upregulation in human eosinophils via a pertussis toxin-sensitive heterotrimeric guanine nucleotide-binding protein.
Blood
88:3195,
1996[Abstract/Free Full Text]
34.
Rothenberg ME,
Ownbey R,
Mehlhop PD,
Loiselle PM,
van de Rijn M,
Bonventre JV,
Oettgen HC,
Leder P,
Luster AD:
Eotaxin triggers eosinophil-selective chemotaxis and calcium flux via a distinct receptor and induces pulmonary eosinophilia in the presence of interleukin 5 in mice.
Mol Med
2:334,
1996[Medline]
[Order article via Infotrieve]
35.
Ponath PD,
Qin S,
Post TW,
Wang J,
Wu L,
Gerard NP,
Newman W,
Gerard C,
Mackay CR:
Molecular cloning and characterization of a human eotaxin receptor expressed selectively on eosinophils.
J Exp Med
183:2437,
1996[Abstract/Free Full Text]
36.
Daugherty BL,
Siciliano SJ,
DeMartino JA,
Malkowitz L,
Sirotina A,
Springer MS:
Cloning, expression, and characterization of the human eosinophil eotaxin receptor.
J Exp Med
183:2349,
1996[Abstract/Free Full Text]

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
K. J. Haley, M. E. Sunday, Y. Porrata, C. Kelley, A. Twomey, A. Shahsafaei, B. Galper, L. A. Sonna, and C. M. Lilly
Ontogeny of the eotaxins in human lung
Am J Physiol Lung Cell Mol Physiol,
February 1, 2008;
294(2):
L214 - L224.
[Abstract]
[Full Text]
[PDF]
 | |